 |
        |
David Knaack, Ph.D.Vice President, Product Development Dr. Knaack has made significant contributions to the development of novel biomaterials for medical devices as a product development manager for several biotechnology companies, most recently as Senior Director for R&D at Osteotech, Inc. He is a registered patent agent with strategic intellectual property development experience for growth factor delivery, polymer-tissue composites, and cell line development. Dr. Knaack has published in the fields of composite and biomaterials development as well as tissue engineering and cell and molecular biology. He is a named inventor on six issued U.S. patents. He holds an undergraduate degree in Chemistry from St. Lawrence University and a doctoral degree in Neurochemistry from Cornell University. He completed post doctoral work in Molecular Biology at Harvard Medical School, as a Howard Hughes Fellow. He joined ORTHOCON® in 2006. Return to Leadership |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
ORTHOCON® Names David J. Hart Vice President of Business Operations
March 15, 2012 - Click to Download Canaan Partners Closes $600 Million Fund, Canaan IX January 9, 2012 - Click to Read More |
||
|
||||||
